Abstract
Abstract
Background
The prevalence of hypertension is high and increasing in China in recent years. The treatment and control of hypertension calls for long-term management beyond hospital, which is hard to implement in traditional care settings. Integrated care combined with information technology can promote high-quality healthcare services across the life-course. However, few studies have applied a customized integrated care model in community-based hypertension management in China, catering to the emerging “three-manager” mode. This study aims to identify the effectiveness of a pathway-driven eHealth-based integrated model that implemented as a full-featured telehealth system to facilitate standardized management of hypertension in China.
Methods
The trial has been designed as a 1-year, non-blinded superiority trial with two parallel groups. A total of 402 hypertensive patients who meet the eligibility criteria will be recruited and randomized with a 1:1 allocation. All the participants will receive a mobile device for self-management, which is a part of our telehealth system. Participants in the control group will only use the device for BP measurement and receive regular follow-ups from care providers according to the guidelines. Participants in the intervention group will gain full access to the system and receive intervention based on the proposed model (a well-designed coordinated care pathway consisting of 9 tasks). Outcomes will be measured mainly on three occasions (at inclusion, at 6 months, and at 12 months). The primary outcome is mean change in systolic blood pressure over a 12-month period. Secondary outcomes include changes in diastolic blood pressure, biochemical indexes related to hypertension, lifestyles, self-management adherence, and hypertension awareness, as well as work efficiency of care providers.
Discussion
This study aims to investigate whether a pathway-driven eHealth-based integrated care model based on the “three-manager” mode will improve hypertension control in China. Success of the model would help improve the quality of present community-based management procedures and benefit more patients with uncontrolled hypertension.
Trial registration
Chinese Clinical Trial Registry ChiCTR1900027645. Registered on November 22, 2019.
Funder
National Key Research and Development Program of China
Key Research and Development Program of Ningxia Hui Autonomous of China
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Medicine (miscellaneous)
Reference40 articles.
1. Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, et al. Status of hypertension in China. Circulation. 2018;137(22):2344–56. https://doi.org/10.1161/CIRCULATIONAHA.117.032380.
2. Reynolds R, Dennis S, Hasan I, Slewa J, Chen W, Tian D, et al. A systematic review of chronic disease management interventions in primary care. BMC Fam Pract. 2018;19(1):11. https://doi.org/10.1186/s12875-017-0692-3.
3. Nguyen Q, Dominguez J, Nguyen L, Gullapalli N. Hypertension management: an update. Am Heal Drug Benefits. 2010;3(1):47–56 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25126308.
4. WHO Regional Office for Europe. Integrated care models: an overview [Internet]. 2016. available from: https://www.euro.who.int/__data/assets/pdf_file/0005/322475/Integrated-care-models-overview.pdf. Accessed 18 Jan 2020.
5. WHO Regional Office for Europe. Strengthening people-centred health systems in the WHO European Region: framework for action on integrated health services delivery [Internet]. 2016. available from: https://www.euro.who.int/__data/assets/pdf_file/0004/315787/66wd15e_FFA_IHSD_160535.pdf. Accessed 18 Jan 2020.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献